ClinVar Miner

Submissions for variant NM_000059.3(BRCA2):c.9190G>A (p.Asp3064Asn) (rs80359177)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV001083475 SCV000073755 likely benign Hereditary breast and ovarian cancer syndrome 2019-12-31 criteria provided, single submitter clinical testing
Ambry Genetics RCV000130150 SCV000184984 likely benign Hereditary cancer-predisposing syndrome 2018-10-26 criteria provided, single submitter clinical testing Other data supporting benign classification;In silico models in agreement (benign)
GeneDx RCV000440778 SCV000517839 likely benign not specified 2017-06-07 criteria provided, single submitter clinical testing This variant is considered likely benign or benign based on one or more of the following criteria: it is a conservative change, it occurs at a poorly conserved position in the protein, it is predicted to be benign by multiple in silico algorithms, and/or has population frequency not consistent with disease.
Integrated Genetics/Laboratory Corporation of America RCV000440778 SCV000695216 uncertain significance not specified 2019-11-27 criteria provided, single submitter clinical testing Variant summary: BRCA2 c.9190G>A (p.Asp3064Asn) results in a conservative amino acid change located in the BRCA2, OB3 domain (IPR015188) of the encoded protein sequence. Five of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 1.6e-05 in 251296 control chromosomes (gnomAD). The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.9190G>A has been reported in the literature in individuals without information on cancer phenotype (Qian_2018, Pritchard_2018). These reports do not provide unequivocal conclusions about association of the variant with Hereditary Breast and Ovarian Cancer. Co-occurrence with a pathogenic variant has been reported (BRCA2 c.6408_6414delAAATGTT, p.N2137fs*29; Internal testing), providing supporting evidence for a benign role. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Seven ClinVar submitters (evaluaton after 2014) cite the variant as benign/likely benign (n=5) and as uncertain significance (n=2). Based on the evidence outlined above, the variant was classified as VUS-possibly benign.
Counsyl RCV000077462 SCV000786192 uncertain significance Breast-ovarian cancer, familial 2 2018-03-21 criteria provided, single submitter clinical testing
Color RCV000130150 SCV000911250 benign Hereditary cancer-predisposing syndrome 2016-12-19 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000077462 SCV000109260 benign Breast-ovarian cancer, familial 2 2012-03-20 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA2) RCV000077462 SCV000147562 uncertain significance Breast-ovarian cancer, familial 2 2002-05-29 no assertion criteria provided clinical testing
Mayo Clinic Genetic Testing Laboratories,Mayo Clinic RCV000590167 SCV000778723 uncertain significance not provided 2015-10-07 no assertion criteria provided clinical testing
True Health Diagnostics RCV000130150 SCV000886677 likely benign Hereditary cancer-predisposing syndrome 2018-08-07 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.